

## Midazolam

<b>Potential SALAD</b> Ensure selection of the correct <b>strength</b> of midazolam ampoule	
<b>CAUTION: High Administration Risk Rating</b>	
<b>Form</b>	10mg per 2mL ampoule (5mg/mL) 10mg per 5mL ampoule (2mg/mL)
<b>Reconstitution</b>	Already in solution <ul style="list-style-type: none"> <li><b>Draw up using a 5 micron filter needle</b></li> <li><b>Use gloves when opening ampoules</b></li> </ul>
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9% Glucose 5%
<b>Administration</b>	<p><b><u>IV Injection</u></b> Administer at a rate of 2mg/min.</p> <p><b><u>IV Infusion</u></b> Refer to ITU guideline.</p> <p><b><u>SC Injection</u></b> Give required dose by SC injection</p> <p><b><u>Continuous SC Infusion (Unlicensed)</u></b> Use 10mg per 2mL ampoule and dilute with sodium chloride 0.9%.</p>
<b>Antidote</b>	Flumazenil is a specific benzodiazepine antagonist and must be available to rapidly reverse respiratory depression when administering midazolam.
<b>Extravasation</b>	Midazolam has a low pH and may cause venous irritation and tissue damage in cases of extravasation. If a central venous access device is unavailable, administer via a large peripheral vein monitoring insertion site closely. Re-site cannula at first signs of inflammation.
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>Unlicensed for use in palliative care.</li> <li>Administration via syringe driver is unlicensed and may increase the administration risk rating. To mitigate these risks:               <ul style="list-style-type: none"> <li>Contact the Pharmacy Department or Palliative care team for further guidance.</li> <li>Consult the Palliative Care Formulary accessible on <a href="http://www.medicinescomplete.com">www.medicinescomplete.com</a> or the Syringe Driver Survey Database (SDSD) (available after registration on <a href="http://www.palliativedrugs.com">www.palliativedrugs.com</a>) for <a href="#">guidance on syringe driver compatibility</a>.</li> </ul> </li> </ul>

**Information provided relates to Hypnovel® manufactured by Cheplapharm**

*This information has been summarised to act as a guide for those administering IV medication. The monograph should be used in conjunction with the drug data sheet and BNF for information on dose, adverse effects, cautions and contra-indications. Further information is available from Pharmacy on 22146 or 22542*